Skip to main content

Colorectal Cancer Test Supply Agreement Extended by Quest Diagnostics, Clinical Genomics

NEW YORK (360Dx) – Clinical Genomics and Quest Diagnostics today announced a five-year extension to a US supply agreement for the InSure One fecal immunochemical test (FIT).

Clinical Genomics manufacturers FIT tests, including InSure One FIT. Under the supply agreement extension, Quest will continue to provide the tests to physicians and organized provider groups across the US, including specialized programs to improve colorectal cancer screening rates for accountable care organizations and other organizations focused on value-based care models.

The agreement builds on a longstanding supply agreement between the companies for InSure FIT and

InSure One FIT. Quest will continue to provide broad access to both test products in the US. Quest is also an investor in Clinical Genomics.

InSure One is a US Food and Drug Administration-cleared FIT for detecting blood in stool as an aid in the detection of lower gastrointestinal bleeding. Conditions associated with lower gastrointestinal bleeding include colorectal cancer, iron deficiency anemia, diverticulitis, ulcerative colitis, polyps, and adenomas.

InSure One FIT is the only test performed using toilet water collected from a single bowel movement. InSure One FIT employs a patented brush sampling method through which a water sample is collected from the toilet bowl by simply brushing the surface of the stool to release any blood into the surrounding water, rather than having to collect a stool sample or smear feces.

"We are pleased to continue this important partnership with Quest Diagnostics ensuring that screening programs have broad access to InSure One, an easy-to-use FIT that may lead to improved patient compliance," Clinical Genomics Chief Commercial Officer Betsy Hanna said, in a statement.

Annual FIT is recommended by the American Cancer Society for screening programs to detect the early signs of adenomatous polyps, precursors to cancer, and colorectal cancer. Recently, the ACS updated its recommendations, lowering the screening age from 50 to 45 years.